Skin cancer decisions — 2025

The Board remands the claim for service connection for skin cancer due to new and relevant evidence being submitted, specifically a December 2024 VA examination.

The Board remands the case to obtain an addendum opinion from a new examiner regarding the service connection for melanoma, considering all toxic exposures during military service.

The Board denied the Veteran's claim for an initial compensable rating for myeloma skin cancer, posterior trunk scar and remanded the issue of entitlement to an initial compensable rating for tinea versicolor disability.

The Board remands the matter for an addendum opinion to address whether any current skin disability pre-existed service and, if so, whether it was aggravated by service. The examiner must also opine on whether any current skin disabilities were incurred in or caused by service, including Agent Orange exposure.

The Board granted a disability rating of 10 percent for melanoma, in remission, with residual scars and denied compensable ratings for the same condition on the left upper extremity and posterior trunk. The claim for glaucoma was remanded for further development.

The Board denied the Veteran's claims for increased ratings for skin cancer lesion removal residual scars of the anterior trunk, left upper extremity, and posterior trunk as they do not meet the criteria for a compensable rating.

The Board granted service connection for stage 3 melanoma of the right 5th digit and right axilla, to include any residuals, based on the Veteran's exposure to an herbicide agent during active service in Vietnam.

The Board remands the claims for service connection due to a duty to assist error, requiring adequate medical nexus opinions.

The appeal of the issue of entitlement to service connection for scars, residuals, skin cancer is dismissed due to the Veteran's death.

The Board remands the claims for service connection for various conditions, including erectile dysfunction, peripheral neuropathy, actinic keratosis, hypertension, diabetes mellitus type II, stroke residuals, and coronary artery disease, due to a pre-decisional duty to assist error in not providing VA examinations and medical opinions.

The Board remands the Veteran's claim for service connection for basal cell carcinoma, also claimed as reoccurring skin cancer, to obtain an adequate medical opinion addressing the Veteran's in-service toxic exposures.

The Board granted service connection for prostate cancer and skin cancer, finding the evidence to be at least in relative equipoise.

The Board remands the claims for service connection for prostate cancer and skin cancer to correct a pre-decisional duty to assist error.

The appeal for service connection for PTSD, bilateral hearing loss, and duodenal ulcer was dismissed due to procedural defects. The appeal for skin cancer was denied as there is no competent evidence linking the condition to herbicide exposure.

The Board granted readjudication of the claim for service connection for melanoma, but denied readjudication for cervical strain, sinusitis, and myeloma.

The Board granted service connection for prostate cancer and skin lesion (claimed as melanoma) based on the evidence of record.

The Board denied service connection for neuropathy of the right lower extremity and melanomas, both due to a lack of evidence supporting their direct or secondary relationship to the Veteran's military service.

The Board denied service connection for squamous cell carcinoma, finding that the evidence did not support a link between the Veteran's skin cancer and his military service, including exposure to herbicide agents.

The Board remands the claim for further development to determine if the immunotherapy treatment the Veteran is receiving qualifies as antineoplastic therapy.

The Board denied the veteran's claims for earlier effective dates and initial ratings, finding that the evidence did not support an earlier date of entitlement or a higher rating.